The management of Chronic Hand Eczema : A retrospective patient record review
© 2024 LEO Pharma. Contact Dermatitis published by John Wiley & Sons Ltd..
BACKGROUND: Chronic Hand Eczema (CHE) is a heterogeneous fluctuating inflammatory disease that represents a significant burden. Effective treatment options for moderate to severe CHE are limited.
OBJECTIVES: To assess how patients with moderate to severe CHE are treated in clinical practice.
METHODS: A retrospective, physician-led patient record review assessed the demographic, clinical and treatment characteristics of patients aged ≥18 years with CHE across seven countries. Each participating physician was requested to review records for their three most recent patients with moderate to severe CHE treated with a topical or systemic therapy.
RESULTS: A total of 264 physicians, of whom 88.6% were dermatologists and 70.1% were predominantly or partly hospital-based, reviewed the records of 792 patients. Signs were present on hands only in 56.4% of patients and the mean time on current treatment was 16.7 months. Overall, 62.9% of patients received systemic therapy and almost one-quarter (23.4%) were treated with a biologic; 28.6% of patients were only treated with topical corticosteroids and/or topical calcineurin inhibitors.
CONCLUSION: In patients with moderate to severe CHE, most received systemic therapy with one-quarter on biologic therapy. However, given that many of these treatments have limited evidence of efficacy in CHE, there is a need for studies specifically in patients with CHE as well as new therapeutic options.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:90 |
|---|---|
| Enthalten in: |
Contact dermatitis - 90(2024), 4 vom: 23. März, Seite 365-371 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Borg, Emma [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chronic Hand Eczema |
|---|
| Anmerkungen: |
Date Completed 13.03.2024 Date Revised 13.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/cod.14477 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366546880 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366546880 | ||
| 003 | DE-627 | ||
| 005 | 20240313234009.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/cod.14477 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1326.xml |
| 035 | |a (DE-627)NLM366546880 | ||
| 035 | |a (NLM)38164049 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Borg, Emma |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The management of Chronic Hand Eczema |b A retrospective patient record review |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.03.2024 | ||
| 500 | |a Date Revised 13.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 LEO Pharma. Contact Dermatitis published by John Wiley & Sons Ltd. | ||
| 520 | |a BACKGROUND: Chronic Hand Eczema (CHE) is a heterogeneous fluctuating inflammatory disease that represents a significant burden. Effective treatment options for moderate to severe CHE are limited | ||
| 520 | |a OBJECTIVES: To assess how patients with moderate to severe CHE are treated in clinical practice | ||
| 520 | |a METHODS: A retrospective, physician-led patient record review assessed the demographic, clinical and treatment characteristics of patients aged ≥18 years with CHE across seven countries. Each participating physician was requested to review records for their three most recent patients with moderate to severe CHE treated with a topical or systemic therapy | ||
| 520 | |a RESULTS: A total of 264 physicians, of whom 88.6% were dermatologists and 70.1% were predominantly or partly hospital-based, reviewed the records of 792 patients. Signs were present on hands only in 56.4% of patients and the mean time on current treatment was 16.7 months. Overall, 62.9% of patients received systemic therapy and almost one-quarter (23.4%) were treated with a biologic; 28.6% of patients were only treated with topical corticosteroids and/or topical calcineurin inhibitors | ||
| 520 | |a CONCLUSION: In patients with moderate to severe CHE, most received systemic therapy with one-quarter on biologic therapy. However, given that many of these treatments have limited evidence of efficacy in CHE, there is a need for studies specifically in patients with CHE as well as new therapeutic options | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Chronic Hand Eczema | |
| 650 | 4 | |a contact dermatitis | |
| 650 | 4 | |a drug therapy | |
| 650 | 4 | |a real-world evidence | |
| 650 | 7 | |a Dermatologic Agents |2 NLM | |
| 700 | 1 | |a Munro, Duncan |e verfasserin |4 aut | |
| 700 | 1 | |a Thoning, Henrik |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Contact dermatitis |d 1981 |g 90(2024), 4 vom: 23. März, Seite 365-371 |w (DE-627)NLM000341193 |x 1600-0536 |7 nnns |
| 773 | 1 | 8 | |g volume:90 |g year:2024 |g number:4 |g day:23 |g month:03 |g pages:365-371 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/cod.14477 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 90 |j 2024 |e 4 |b 23 |c 03 |h 365-371 | ||